HAVAS 18.950 € (+1,34 %) 
SCHNEIDER ELECTRIC 306.400 € (-0,92 %) SODEXO 56.800 € (-0,87 %) SANOFI 75.520 € (-1,19 %) MERCIALYS 11.600 € (-0,17 %) UMG 14.945 € (+2,01 %) PROSUS 37.395 € (-1,85 %) POSTNL 0.915 € (-0,27 %) EUROPLASMA 0.001 € (-25,00 %) BIOMERIEUX 73.100 € (+0,14 %) AXA 45.050 € (+0,92 %) Vusion 130.900 € (-1,80 %) 
ARCELORMITTAL SA 63.740 € (+0,13 %) ABIVAX 102.700 € (-3,66 %) FDJ UNITED 22.400 € (+0,67 %) VIRIDIEN 99.400 € (+2,47 %) BIOPHYTIS BSA 0.009 € (+260,00 %) OCI 4.060 € (+0,20 %) 
SHELL PLC 38.970 € (+0,95 %) LHYFE 2.400 € (+12,15 %) PHARMING GROUP 0.994 € (-3,33 %) KERING 268.550 € (-0,76 %) TELEPERFORMANCE 70.860 € (+2,55 %) WOLTERS KLUWER 69.780 € (+2,14 %) ESSILORLUXOTTICA 162.550 € (-0,73 %) ASML HOLDING 1 579.600 € (-1,85 %) CRCAM LANGUED CCI 91.000 € (0,00 %) PUBLICIS GROUPE SA 101.800 € (+1,82 %) ALFEN 13.360 € (+4,38 %) ING GROEP N.V. 30.885 € (+0,21 %) SAINT GOBAIN 83.940 € (-0,24 %) LVMH 458.400 € (-0,35 %) ARTMARKET COM 3.090 € (+6,55 %) GROUPE OKWIND 0.256 € (+6,22 %) BE SEMICONDUCTOR 233.500 € (-0,72 %) NEXANS 140.000 € (-1,75 %) ORANGE 16.405 € (+0,74 %) VALNEVA 3.000 € (+22,20 %) CAPGEMINI 108.300 € (+2,17 %) 
X-FAB 6.665 € (-3,89 %) SAFRAN 360.500 € (+0,70 %) 
FLOW TRADERS 27.560 € (-0,14 %) AIRBUS 215.400 € (+1,17 %) MEDINCELL 24.100 € (-1,63 %) DANONE 67.240 € (-1,09 %) UNILEVER 53.870 € (-0,55 %) BIC 66.400 € (-0,45 %) BNP PARIBAS ACT.A 112.100 € (-0,27 %) ARCADIS 43.380 € (+0,37 %) OREGE 0.321 € (-4,46 %) GECINA 74.000 € (-0,07 %) KAUFMAN ET BROAD 25.050 € (+0,40 %) AIR LIQUIDE 168.260 € (-0,52 %) CROSSJECT 1.446 € (+0,84 %) RELX 29.780 € (+1,64 %) SOLUTIONS 30 SE 0.625 € (+0,64 %) VEOLIA ENVIRON. 34.030 € (-0,56 %) EBUSCO HOLDING 0.223 € (-4,51 %) COMPAGNIE ODET 1 342.000 € (+0,60 %) INVENTIVA 3.880 € (-3,72 %) |
15/08/2026 00:50
Revive Therapeutics Reports Grant of OptionsTORONTO, ON / ACCESS Newswire / August 14, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today announced the Board of Directors of Revive has authorized the grant of an aggregate of 15,500,000 incentive stock options to key members of our team, including directors, officers, and consultants. The stock options have an exercise price of $0.05 per share for a period of five years. All Options were granted pursuant to the Company's 10% rolling stock option plan (the "Plan") and are subject to the terms of the Plan, the applicable grant agreement and the requirements of the CSE. These stock options are an essential component of our strategy to drive performance and incentivize excellence as we advance our corporate objectives. About Revive Therapeutics Ltd. Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness. For more information, visit www.revivethera.com. For more information, please contact: Michael Frank SOURCE: Revive Therapeutics Ltd. View the original press release on ACCESS Newswire Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière